Cigna’s Shift to Net Drug Pricing: Why Transparency Alone Isn’t Enough for Plan Sponsors

Cigna’s announcement that Evernorth will move away from traditional manufacturer rebates and toward up-front, net drug pricing reflects a broader industry reckoning: opaque pricing models are no longer sustainable in a healthcare environment under intense cost scrutiny. For HR and benefits professionals, this shift is welcome. Net pricing promises clearer visibility into drug costs and a more straightforward financial model.